Open Access
Open access
MDPI
Cancers
,  том 16 ,  издание 16 ,  страницы 2854

Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies

Тип публикации: Journal Article
Дата публикации: 2024-08-15
MDPI
scimago Q1
wos Q2
white level БС1
SJR: 1.462
CiteScore: 8.8
Impact factor: 4.4
ISSN: 20726694
Краткое описание

Human epidermal growth factor 2 (HER2) is a tyrosine kinase receptor that interacts with multiple signaling pathways related to cellular growth and proliferation. Overexpression or amplification of HER2 is linked to various malignancies, and there have been decades of research dedicated to targeting HER2. Despite the landmark ToGA trial, progress in HER2-positive gastrointestinal malignancies has been hampered by drug resistance. This review examines current HER2 expression patterns and therapies for gastroesophageal, colorectal, biliary tract, and small bowel cancers, while dissecting potential resistance mechanisms that limit treatment effectiveness.

Для доступа к списку цитирований публикации необходимо авторизоваться.
 Войти с ORCID

Топ-30

Журналы

1
Taiwanese Journal of Obstetrics and Gynecology
Taiwanese Journal of Obstetrics and Gynecology, 1, 25%
Taiwanese Journal of Obstetrics and Gynecology
1 публикация, 25%
Biomedicines
Biomedicines, 1, 25%
Biomedicines
1 публикация, 25%
Hepatology
Hepatology, 1, 25%
Hepatology
1 публикация, 25%
Critical Reviews in Oncology/Hematology
Critical Reviews in Oncology/Hematology, 1, 25%
Critical Reviews in Oncology/Hematology
1 публикация, 25%
1

Издатели

1
2
Elsevier
Elsevier, 2, 50%
Elsevier
2 публикации, 50%
MDPI
MDPI, 1, 25%
MDPI
1 публикация, 25%
Ovid Technologies (Wolters Kluwer Health)
Ovid Technologies (Wolters Kluwer Health), 1, 25%
Ovid Technologies (Wolters Kluwer Health)
1 публикация, 25%
1
2
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
 Войти с ORCID
Метрики
4
Поделиться
Цитировать
ГОСТ |
Цитировать
ГОСТ Скопировать
Mo C. et al. Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies // Cancers. 2024. Vol. 16. No. 16. p. 2854.
ГОСТ со всеми авторами (до 50) Скопировать
Mo C., Sterpi M., Jeon H., Bteich F. Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies // Cancers. 2024. Vol. 16. No. 16. p. 2854.
RIS |
Цитировать
RIS Скопировать
TY - JOUR
DO - 10.3390/cancers16162854
UR - https://www.mdpi.com/2072-6694/16/16/2854
TI - Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies
T2 - Cancers
AU - Mo, Christiana
AU - Sterpi, Michelle
AU - Jeon, Hyein
AU - Bteich, Fernand
PY - 2024
DA - 2024/08/15
PB - MDPI
SP - 2854
IS - 16
VL - 16
PMID - 39199625
SN - 2072-6694
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2024_Mo,
author = {Christiana Mo and Michelle Sterpi and Hyein Jeon and Fernand Bteich},
title = {Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies},
journal = {Cancers},
year = {2024},
volume = {16},
publisher = {MDPI},
month = {aug},
url = {https://www.mdpi.com/2072-6694/16/16/2854},
number = {16},
pages = {2854},
doi = {10.3390/cancers16162854}
}
MLA
Цитировать
MLA Скопировать
Mo, Christiana, et al. “Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies.” Cancers, vol. 16, no. 16, Aug. 2024, p. 2854. https://www.mdpi.com/2072-6694/16/16/2854.
Ошибка в публикации?